Amy Ford Turner, DO
Pulmonary Disease · Springfield, MONPI 1710188040
Payments from drug & device makers
Across 236 payments — averaging $51.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$716
- GSK$483
- Boehringer Ingelheim$213
- Genentech USA, Inc.$208
- Mylan Specialty L.p.$205
- plus $2K from 32 others
What the payments were for
- Travel & lodging$5665%
- Food & beverage$4,08034%
- Education$7,50062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $8,333 |
| AstraZeneca | 40 | $716 |
| GSK | 38 | $483 |
| Boehringer Ingelheim | 12 | $213 |
| Genentech USA, Inc. | 12 | $208 |
| Mylan Specialty L.p. | 14 | $205 |
| United Therapeutics Corporation | 9 | $178 |
| Grifols USA, LLC | 10 | $177 |
| AbbVie(2 entities) | 9 | $159 |
| Jazz Pharmaceuticals Inc. | 5 | $99 |
| CSL Behring | 4 | $93 |
| Sanofi | 3 | $93 |
| Novartis | 5 | $93 |
| Pfizer | 6 | $93 |
| Insmed, Inc. | 4 | $85 |
| Idorsia Pharmaceuticals US Inc | 5 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Philips North America LLC | 4 | $69 |
| Merck | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Electromed, Inc. | 5 | $59 |
| Circassia Inc. | 4 | $58 |
| Actelion Pharmaceuticals US, Inc. | 4 | $52 |
| Amgen | 3 | $46 |
| Lilly USA, LLC | 2 | $42 |
| Viatris Specialty LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 3 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Shionogi Inc | 1 | $21 |
| ZOLL Respicardia, Inc. | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Inari Medical, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- Da Vinci Surgical System$2,123
How this compares
$12,146 in reported general payments places this provider in the 75th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 357 | $277,150 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $68,032 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $52,848 |
| NucalaMepolizumab | 12 | $41,814 |
| Spiriva RespimatTiotropium Bromide | 71 | $38,502 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $33,033 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 52 | $27,595 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $26,664 |
| Spiriva HandihalerTiotropium Bromide | 21 | $17,975 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 38 | $15,016 |
| XolairOmalizumab | 14 | $14,750 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $13,099 |
| Pirfenidone | 20 | $11,925 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 60 | $8,978 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $483 | $427,899552 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $213 | $92,761160 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $716 | $80,963145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Springfield
- Madhu Kalyan PendurthiSpringfield$470K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.